Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

被引：6
|
作者：
Alsawah, Fares [1 ]
Benitez, Lydia [2 ]
Choi, Sarah [3 ]
Marini, Bernard [2 ]
Perissinotti, Anthony [2 ]
Skyles, Amy [2 ]
Burke, Patrick [4 ]
Pettit, Kristen [4 ]
Crouch, Ashley [4 ]
Fox, Heather [4 ]
Bixby, Dale [4 ]
机构：
[1] Michigan Med, Dept Internal Med, Ann Arbor, MI USA
[2] Michigan Med, Dept Pharm Serv & Clin Sci, Ann Arbor, MI USA
[3] Univ Michigan, Michigan Med, Dept Pathol, Ann Arbor, MI 48109 USA
[4] Michigan Med, Dept Internal Med, Div Hematol & Med Oncol, F4811A UH South,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA
来源：
BLOOD ADVANCES | 2019年 / 3卷 / 21期
关键词：
ANTIBODY;
D O I：
10.1182/bloodadvances.2019000289
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3333 / 3336
页数：4
相关论文
共 50 条
  • [1] Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration
    Mori, Jinichi
    Oshima, Kumi
    Kimura, Satoshi
    Ikezoe, Takayuki
    CASE REPORTS IN HEMATOLOGY, 2020, 2020
  • [2] Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab
    Herbaux, Charles
    Poulain, Stephanie
    Roos-Weil, Damien
    Bay, Jacques-Olivier
    Guillermin, Yann
    Lemonnier, Francois
    Laribi, Kamel
    Visanica, Sorin
    Moreaux, Jerome
    Gonzalez, Hugo
    Jullien, Maxime
    El Yamani, Abderrazak
    Debarri, Houria
    Godet, Sophie
    Morschhauser, Franck
    Tournilhac, Olivier
    Davids, Matthew S.
    Ysebaert, Loic
    BLOOD, 2021, 138
  • [3] COST-EFFECTIVENESS OF ALEMTUZUMAB FOR T-CELL PROLYMPHOCYTIC LEUKEMIA
    Lu, Lanting
    Peters, Jaime
    Roome, Chris
    Stein, Ken
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (03) : 241 - 248
  • [4] Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia
    Cheung, Carol Y. M.
    Leung, Rock Y. Y.
    Tam, Anthony Raymond
    Sim, Joycelyn P. Y.
    Kwong, Yok-lam
    ANNALS OF HEMATOLOGY, 2023, 102 (02) : 483 - 485
  • [5] Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia
    Carol Y. M. Cheung
    Rock Y. Y. Leung
    Anthony Raymond Tam
    Joycelyn P. Y. Sim
    Yok-lam Kwong
    Annals of Hematology, 2023, 102 : 483 - 485
  • [6] Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan
    Yamaguchi, Motoko
    Fukuhara, Noriko
    Takizawa, Jun
    Ishitsuka, Kenji
    Yokohama, Akihiko
    Miyazaki, Kana
    Nato, Yuma
    Ichikawa, Satoshi
    Mitobe, Masaki
    Shima, Kodai
    Miyazawa, Yuri
    Izutsu, Koji
    Suzuki, Ritsuro
    Nagai, Hirokazu
    Nakamura, Naoya
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2024, 64 (03) : 216 - 222
  • [7] T-cell prolymphocytic leukemia: Potential diagnostic pitfalls
    Dessart, P.
    Lemaire, P.
    Le Du, K.
    Sandrini, J.
    Prophette, B.
    Maillard, H.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2014, 141 (12): : 777 - 781
  • [8] T-cell prolymphocytic leukemia
    Khot, Amit
    Dearden, Claire
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (03) : 365 - 371
  • [9] T-cell prolymphocytic leukemia
    Claire E. Dearden
    Medical Oncology, 2006, 23 : 17 - 22
  • [10] Rhodococcus equi infection after alemtuzumab therapy for T-cell Prolymphocytic leukemia
    Meeuse, Jan J.
    Sprenger, Herman G.
    van Assen, Sander
    Leduc, Dominique
    Daenen, Simon M. G. J.
    Arends, Jan P.
    van der Werf, Tjip S.
    EMERGING INFECTIOUS DISEASES, 2007, 13 (12) : 1942 - 1943
12345